Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX)
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NextCure (NXTC)
In a report issued on July 1, Emily Bodnar from H.C. Wainwright maintained a Buy rating on NextCure, with a price target of $3.00. The company's shares closed last Thursday at $0.44.
According to TipRanks.com, Bodnar is ranked 0 out of 5 stars with an average return of -6.6% and a 29.4% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., Acrivon Therapeutics, Inc., and TransCode Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NextCure with a $3.00 average price target.
Lexaria Bioscience (LEXX)
In a report issued on July 1, Yi Chen from H.C. Wainwright reiterated a Buy rating on Lexaria Bioscience, with a price target of $5.00. The company's shares closed last Thursday at $0.90.
According to TipRanks.com, Chen 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.9% and a 37.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as OKYO Pharma Limited Sponsored ADR, Orchestra BioMed Holdings, and Bausch + Lomb Corporation.
The the analyst consensus on Lexaria Bioscience is currently a Hold rating.
Travere Therapeutics (TVTX)
Travere Therapeutics received a Buy rating and a $30.00 price target from H.C. Wainwright analyst Joseph Pantginis on July 1. The company's shares closed last Thursday at $15.01.
According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.8% and a 30.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Adlai Nortye Ltd. Sponsored ADR, and Bioline RX Ltd Sponsored ADR.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Travere Therapeutics with a $34.00 average price target, representing a 128.8% upside. In a report issued on June 16, Evercore ISI also maintained a Buy rating on the stock with a $45.00 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 days ago
- Business Insider
Surge AI's CEO says he would never hire these 2 roles at an early-stage startup
Product managers and data scientists have no place on a founding team, said Surge AI's CEO, Edwin Chen. Chen said on an episode of "No Priors Podcast" published Thursday that he often hears early-stage founders list the roles among their first five to 10 hires. "This is just wild to me," he said. Chen, who used to be a data scientist himself, said he would not hire data scientists early. "Data scientists are great when you want to optimize your product by 2% or 5%, but that's definitely not what you want to be doing when you start a company," he said. "You're trying to swing for 10x or 100x changes, not worrying and nitpicking about small percentage points that are just noise anyway." The founder of the data labeling startup also said product managers don't make sense early on. He said that the role becomes useful only once engineers no longer have the time or capacity to drive product direction. "Your engineer should be hands-on. They should be having great ideas as well," he said. " Product managers are great when your company gets big enough, but at the beginning, you should be thinking about yourself, about what product you want to build," he added. Surge AI and Chen did not respond to a request for comment from Business Insider. The great product manager debate Chen's comments come as the debate continues in the startup world over the role of product managers. Product managers have been referred to — both affectionately and critically — as "mini-CEOs" of the products they oversee. They act as a bridge among engineers, sales teams, customer service, and other departments, ensuring that products align with user needs. But the role has become a polarizing one, with some tech workers arguing that product managers add little value, Business Insider's Amanda Hoover reported in November. Microsoft wants to increase the number of engineers relative to product or program managers, BI's Ashley Stewart reported in March. Other companies like Airbnb and Snap are rethinking the need for product managers. The call for executives to go " founder mode" — a concept coined by the Y Combinator cofounder Paul Graham and touted by Airbnb's CEO, Brian Chesky — has some leaders questioning whether they should delegate product decisions to product managers. In 2023, Chesky merged product management with marketing, and Snap told The Information in the same year that it laid off 20 product managers to help speed up the company's decision-making. Others believe product managers' influence will only grow in the age of AI. Microsoft's chief technology officer, Kevin Scott, said on an episode of the "Twenty Minute VC" podcast published in March that product managers play a crucial role in setting up "feedback loops" to make AI agents better.
Business Insider
2 days ago
- Business Insider
NextCure presents new preclinical data on osteogenesis imperfecta treatment
NextCure (NXTC) announced the presentation of new preclinical data in a well-established model of osteogenesis imperfecta demonstrating that treatment with NC605, a novel anti-Siglec-15 antibody, achieved improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment. The data were presented at the Brittle Bone Society Meeting on July 24th, 2025. These results demonstrate that NC605 could be a highly effective treatment for OI, also known as brittle bone disease. OI is a rare disorder that results in high bone turnover, abnormal bone formation, bone fragility and recurrent fractures. There is no cure for OI. Current anti-resorptive treatments inhibit both bone loss and bone formation leading to an increase in bone density, but overall poor bone quality. In contrast, NC605 has been shown to inhibit bone loss and to produce new bone, with increased quality and density. Fracture incidence and bone architecture were assessed in male and female OI mice treated with weekly 20 mg/kg of surrogate antibody NP159 and compared to control groups treated with twice weekly 50 mg/kg anti-sclerostin or saline. NP159 increased cortical and trabecular bone mineral density, tissue mineral density, cortical thickness and decreased trabecular separation compared to saline-treated mice. 'In a mouse model of moderate-to-severe OI, NP159, a surrogate murine antibody for NC605, improved trabecular and cortical bone density and reduced fracture incidence comparable to anti-sclerostin,' said Priyanka Kothari, Ph.D., NextCure's Director, Translational Research. 'There is currently no standard of care approved by the FDA for patients with OI and NC605 has the potential to provide significant therapeutic benefit for patients.'
Yahoo
2 days ago
- Yahoo
China plans network to sell surplus computing power in crackdown on data centre glut
(Reuters) -China is taking steps to build a network to sell computing power and curb the unwieldy growth of data centres after thousands of local government-backed centres that sprouted in the country caused a capacity glut and threatened their viability. The state planner is conducting a nationwide assessment of the sector after a three-year data centre building boom, according to two sources familiar with the matter and a document seen by Reuters. Beijing is also seeking to set up a national, state-run cloud service for harnessing surplus computing power, according to Chinese government policy advisers. The Ministry of Industry and Information Technology (MIIT) is collaborating with China's three state telecoms companies on ways to connect the data centres in a network to create a platform that can sell the computing power, they said. Computing power is a crucial element in the race for technological supremacy between China and the U.S. Besides being an embarrassment for Beijing, unused computing power and financially shaky data centres could hinder China's ambitions in the development of artificial intelligence capabilities. "Everything will be handed over to our cloud to perform unified organisation, orchestration, and scheduling capabilities," Chen Yili, deputy chief engineer at the China Academy of Information and Communications Technology, a think tank affiliated to the industry ministry, told an industry conference in Beijing last month. Chen did not specify details of the cloud service proposal, but his presentation materials showed China was targeting standardised interconnection of public computing power nationwide by 2028, even as some analysts were skeptical about the plan given the technological challenges it posed. China Mobile, China Unicom and China Telecom, the state-run telecoms companies, and MIIT did not respond to requests for comment. The sources did not want to be identified because of the sensitivities of the issue. NATIONWIDE NETWORK China's data centre building boom kickstarted in 2022 after Beijing launched an ambitious infrastructure project called "Eastern Data, Western Computing", aimed at coordinating data centre construction by concentrating facilities in western regions - where energy costs are cheaper - to meet demand from the eastern economic hubs. Chen said at the June event that the industry ministry has so far licensed at least 7,000 computing centres. A Reuters review of government procurement documents for data centres used in computing shows a surge last year in state investment, totalling 24.7 billion yuan ($3.4 billion), compared to over 2.4 billion yuan in 2023. This year, already 12.4 billion yuan has been invested in these centres, most of it in the far-west region of Xinjiang. But while only 11 such data centre-related projects were cancelled in 2023, over 100 cancellations occurred over the past 18 months, pointing to growing concerns among local governments about returns on their investments. And utilisation rates are estimated to be low, with four sources putting them at around 20%-30%. Driven by expectations that government and state-owned firms will act as buyers, investors and local governments tend to build without considering real market needs, said a project manager who works for a server company that provides products for such data centers. "The idea of building data centers in remote western provinces lacks economic justification in the first place," said Charlie Chai, an analyst with 86Research, adding lower operating costs had to be viewed against degradation in performance and accessibility. To regulate the sector's growth, China's state planner National Development and Reform Commission (NDRC) initiated a nationwide assessment earlier this year that has already tightened scrutiny of new data center projects planned after March 20, and banned local governments from participating in small-sized computing infrastructure projects. The NDRC aims to prevent resource wastage by setting specific thresholds - such as requiring a computing power purchase agreement and a minimum utilisation ratio - to filter out unqualified projects, according to a person familiar with the matter, who did not provide details on the thresholds. NDRC did not respond to a request for comment. CHALLENGES Industry sources and Chinese policy advisers said the formation of a computing power network will not be easy, given that the technology for data centers to efficiently transfer the power to users in real-time remains underdeveloped. When the Chinese government rolled out the Eastern Data, Western Computing project, it targeted a maximum latency of 20 milliseconds by 2025, a threshold necessary for real-time applications such as high-frequency trading and financial services. However, many facilities, especially those built in the remote western regions, still have not achieved this standard, the project manager said. Many of the centres also use different chips from Nvidia and local alternatives such as Huawei's Ascend chips, making it difficult to integrate various AI chips with different hardware and software architectures to create a unified cloud service. Chen, however, was optimistic, describing a vision of the cloud bridging the differences in underlying computing power and the physical infrastructure. "Users do not need to worry about what chips are at the bottom layer; they just need to specify their requirements, such as the amount of computing power and network capacity needed," he said. ($1 = 7.1715 Chinese yuan renminbi)
